Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 34.10 as of 2026-10-06T11:15:58.001Z.
Consensus retrieved: 2026-10-06T09:44:51.840Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T11:15:58.001Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b93e1a23a9dfa9d618f802043383fd7982fccb7d7d65d9ad7aec1877ee2201e0
Forward PE Ratio (34.10) = Dated Quote Price ($62.00) / Consensus Forward EPS ($1.82)
FORWARD PE RATIO
34.10
SECTOR MEDIAN · HEALTHCARE
19.84
median of 118 covered companies
CURRENT VS SECTOR MEDIAN
+71.92%
vs the sector median at left
BrightSpring Health Services, Inc. Common Stock
Market Cap
$12.17B
Forward PE Ratio
34.10
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $12.17B | 34.10 |
| Encompass Health Corporation (EHC)vs › | $12.00B | 19.79 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.36 |
| Baxter International Inc. (BAX)vs › | $12.52B | 11.79 |
| DaVita Inc. (DVA)vs › | $11.47B | 12.10 |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 15.90 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 35.48 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | N/A |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $11.12B | N/A |
Trailing P/E
46.3
reported TTM EPS
Forward P/E
34.1
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.82 implies +35.8% EPS growth vs the reported trailing $1.34.
At the dated quote price of $62.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.82 | $1.70 – $1.95 | 10 | 34.1x |
| 2027-12-31 | $2.31 | $2.12 – $2.49 | 10 | 26.9x |
| 2028-12-31 | $2.81 | $2.24 – $3.38 | 6 | 22.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
